A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents

Canadian Journal of Psychiatry

Volumn 57, Issue 12, 2012, Pages 717-721

  Patten, Scott B ^a   Waheed, Waqar ^b   Bresee, Lauren ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adolescent; Aripiprazole; Children; Clozapine; Olanzapine; Paliperidone; Pharmacoepidemiology; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ATTENTION DEFICIT DISORDER; CANADA; CHILD BEHAVIOR; CONDUCT DISORDER; DRUG MONITORING; FREQUENCY ANALYSIS; HUMAN; MEDICAL LITERATURE; OFF LABEL DRUG USE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE;

EID: 84873815262     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205701202     Document Type: Review

References (31)

1. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet. 2009;373(9657):4-5.
2. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685.
3. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44(6):548-556.
4. Mirandola M, Andretta M, Corbari L, et al. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: Retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf. 2006;15(6):412-420.
5. Percudani M, Barbui C, Fortino I, et al. Epidemiology of firstand second-generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry. 2005;38(3):128-131.
6. Trifiró G, Spina E, Brignoli O, et al. Antipsychotic prescribing pattern among Italian general practitioners: A population-based study during the years 1999-2002. Eur J Clin Pharmacol. 2005;61(1):47-53.
7. Clark AF. Incidences of new prescribing by British child and adolescent psychiatrists: A prospective study over 12 months. J Psychopharmacol. 2004;18(1):115-120.
8. James LP, Abel K, Wilkinson J, et al. Phenothiazine, butyrophenone, and other psychotropic medication poisonings in children and adolescents. J Toxicol Clin Toxicol. 2000;38(6):615-623.
9. Sankaranarayanan J, Puumala SE. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004. Curr Med Res Opin. 2007;23(6):1375- 1385.
10. Montastruc G, Favreliere S, Sommet A, et al. Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol. 2010;69(3):287-294.
11. Forrester MB, Forrester MB. Aripiprazole exposures reported to Texas poison control centers during 2002-2004. J Toxicol Environ Health A. 2006;69(18):1719-1726.
12. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004;65(6):857-863.
13. Pascoe SJ. The adjunctive use of a centralised database in the monitoring of clozapine-related neutropenia. Pharmacoepidemiol Drug Saf. 2003;12(5):395-398.
14. Kornegay CJ, Vasilakis-Scaramozza C, Jick H, et al. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002;63(9):758-762.
15. Spila-Alegiani S, Diana G, Menniti-Ippolito F, et al. Anticholinergic antiparkinsonian therapy in outpatients treated with neuroleptic drugs: A prescription survey. Eur J Clin Pharmacol. 1995;48(6):513-517.
16. Bateman DN, Rawlins MD, Simpson JM, et al. Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. Q J Med. 1986;59(230):549-556.
17. Alessi-Severini S, Biscontri RG, Collins DM, et al. Ten years of antipsychotic prescribing to children: A Canadian population-based study. Can J Psychiatry. 2012;57(1):52-58.
18. Clavenna A, Rossi E, Derosa M, et al. Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr. 2007;166(4):339-347.
19. Sevilla-Dedieu C, Kovess-Masfety V. Psychotropic medication use in children and adolescents: A study from France. J Child Adolesc Psychopharmacol. 2008;18(3):281-289.
20. Acquaviva E, Legleye S, Auleley GR, et al. Psychotropic medication in the French child and adolescent population: Prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry. 2009;9:72.
21. Kalverdijk LJ, Tobi H, van den Berg PB, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv. 2008;59(5):554-560.
22. Rani F, Murray ML, Byrne PJ, et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008;121(5):1002-1009.
23. Zoega H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: A nationwide population-based study. J Child Adolesc Psychopharmacol. 2009;19(6):757-764.
24. Constantine RJ, Tandon R, McPherson M, et al. Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's Medicaid program. J Child Adolesc Psychopharmacol. 2011;21(1):79-84.
25. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13-23.
26. Cooper WO, Hickson GB, Fuchs C, et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158(8):753-759.
27. Pathak P, West D, Martin BC, et al. Evidence-based use of secondgeneration antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-129.
28. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79-83.
29. Alessi-Severini S, Biscontri RG, Collins DM, et al. Utilization and costs of antipsychotic agents: A Canadian population-based study, 1996-2006. Psychiatr Serv. 2008;59(5):547-553.
30. Pringsheim T, Lam D, Patten SB. The pharmacoepidemiology of antipsychotic medications for canadian children and adolescents: 2005-2009. J Child Adolesc Psychopharmacol. 2011;21(6):537-543.
31. Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidencebased recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218-233.